MAPK12

Mitogen-activated protein kinase 12

95,813 patent compounds predicted against MAPK12, 65,260 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL67984	0.89	19/20
SCHEMBL70674	0.60	19/20
SCHEMBL68380	0.75	18/20
SCHEMBL69565	0.68	18/20
SCHEMBL85099	0.68	18/20
SCHEMBL69086	0.68	18/20
SCHEMBL68502	0.67	18/20
SCHEMBL67380	0.65	18/20
SCHEMBL69184	0.65	18/20
SCHEMBL67900	0.64	18/20
Neflamapimod (SCHEMBL156367)	1.00	17/20
SCHEMBL67023	0.73	17/20
SCHEMBL68162	0.71	17/20
SCHEMBL68452	0.70	17/20
SCHEMBL91495	0.66	17/20
SCHEMBL68861	0.64	17/20
SCHEMBL68686	0.62	17/20
SCHEMBL85106	0.61	17/20
SCHEMBL67346	0.60	17/20
SCHEMBL84724	0.60	17/20

Germline variants in MAPK12 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAPK12 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAPK12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.	PHASE3	UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias	PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	PHASE2	RECRUITING
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome	PHASE1/PHASE2	RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Safety, Pharmacokinetics (PK) of AKT and MEK Combination	PHASE1	COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma	PHASE1	WITHDRAWN
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies	PHASE1	RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Expression of EPK in Recurrent Miscarriage	nan	COMPLETED
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma	nan	COMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPK12 binder may also engage these)

Protein	Name	Similarity
Q63538	—	1.000	Q63538 →
O08911	—	1.000	O08911 →
MAPK13	Mitogen-activated protein kinase 13	0.998	landscape →
Q9Z1B7	—	0.997	Q9Z1B7 →
Q9WTY9	—	0.995	Q9WTY9 →
Q9DGE1	—	0.994	Q9DGE1 →
P70618	—	0.993	P70618 →
G4N374	—	0.993	G4N374 →
MAPK14	Mitogen-activated protein kinase 14	0.992	landscape →
Q9N272	—	0.992	Q9N272 →
A0A194WDG1	—	0.992	A0A194WDG1 →
O62618	—	0.992	O62618 →
O13352	—	0.992	O13352 →
O02812	—	0.992	O02812 →
Q4WQR3	—	0.992	Q4WQR3 →
Q9GRU1	—	0.991	Q9GRU1 →
O42376	—	0.990	O42376 →
A1DES4	—	0.990	A1DES4 →
P47811	—	0.990	P47811 →
O61443	—	0.990	O61443 →
B0Y4X4	—	0.990	B0Y4X4 →
Q3T0N5	—	0.989	Q3T0N5 →
Q9I958	—	0.989	Q9I958 →
O44408	—	0.989	O44408 →
A1CAF0	—	0.988	A1CAF0 →
Q17446	—	0.988	Q17446 →
Q9WUI1	—	0.988	Q9WUI1 →
Q9DGE2	—	0.987	Q9DGE2 →
P54666	—	0.987	P54666 →
Q12126	—	0.987	Q12126 →